Antiepileptic that displays distinctive properties from conventional antiepileptic drugs. Displays potent seizure protection in animal models of chronic epilepsy but lacks activity in acute seizure models. Binds synaptic vesicle protein 2A (SV2A) and inhibits Na+-dependent Cl-/HCO3- exchange.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 170.21. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||5.88 mL||29.38 mL||58.75 mL|
|5 mM||1.18 mL||5.88 mL||11.75 mL|
|10 mM||0.59 mL||2.94 mL||5.88 mL|
|50 mM||0.12 mL||0.59 mL||1.18 mL|
References are publications that support the products' biological activity.
Smedt et al (2007) Levetiracetam: the profile of a novel anticonvulsant drug - part I: preclinical data. CNS Drug Rev. 13 43 PMID: 17461889
Ueda et al (2007) Effect of levetiracetam on molecular regulation of hippocampal glutamate and GABA transporters in rats with chronic seizures induced by amygdalar FeCl3 injection. Brain Res. 1151 55 PMID: 17408599
If you know of a relevant reference for Levetiracetam, please let us know.
Keywords: Levetiracetam, supplier, Anti-epileptic, binds, SV2A, Exocytosis, Endocytosis, Protein, Translocation, UCBL059, Keppra, UCB, L059, Translocation,, Exocytosis, &, Endocytosis, Translocation,, Exocytosis, &, Endocytosis, Tocris Bioscience
Citations for Levetiracetam
Citations are publications that use Tocris products.
Currently there are no citations for Levetiracetam. Do you know of a great paper that uses Levetiracetam from Tocris? If so please let us know.
Average Rating:(Based on 0 Reviews)